Ventripoint Diagnostics Ltd. (TSXV:VPT)

Canada flag Canada · Delayed Price · Currency is CAD
0.1900
+0.0050 (2.70%)
Mar 26, 2025, 3:51 PM EST
-17.39%
Market Cap 30.13M
Revenue (ttm) 136.57K
Net Income (ttm) -5.10M
Shares Out 162.88M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,500
Average Volume 339,501
Open 0.1900
Previous Close 0.1850
Day's Range 0.1850 - 0.1900
52-Week Range 0.0800 - 0.3000
Beta 0.28
RSI 62.92
Earnings Date May 1, 2025

About Ventripoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, in... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Hugh MacNaught
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol VPT
Full Company Profile

Financial Performance

In 2023, Ventripoint Diagnostics's revenue was 49,183, a decrease of -27.85% compared to the previous year's 68,167. Losses were -4.87 million, -0.02% less than in 2022.

Financial Statements

News

Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing ...

4 days ago - TheNewswire

Ventripoint Announces Closing of $500,000 Non-Brokered Convertible Debenture Unit Private Placement

Toronto, Ontario, March 21, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces the closing of its previously announced (see press release of...

7 days ago - TheNewswire

Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement

Toronto, Ontario – TheNewswire - March 14, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (...

14 days ago - TheNewswire

Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System

Toronto, Ontario  - TheNewswire - February 27, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and...

4 weeks ago - TheNewswire

Ventripoint Issues Option Grants and Reports Exercise of Options

Toronto, Ontario – TheNewswire – February 11, 2024  - Ventripoint Diagnostics Ltd. (“ Ventripoint  ” or the “  Corporation  ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20, 2025, the Corporation ...

6 weeks ago - TheNewswire

Ventripoint Diagnostics issues shares for payment of debenture interest

Ventripoint Diagnostics issues shares to pay interest on convertible debentures, with shares priced at $0.11 subject to TSXV approval.

2 months ago - Seeking Alpha